A Study of Brexpiprazole in Patients With Major Depressive Disorder

  • participants needed
  • sponsor
    Otsuka Pharmaceutical Co., Ltd.
Updated on 7 August 2022
adjunctive treatment
major depressive disorder
antidepressant therapy
major depressive disorder, recurrent episode


The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.

Condition Major Depressive Disorder
Treatment Placebo, Brexpiprazole
Clinical Study IdentifierNCT03697603
SponsorOtsuka Pharmaceutical Co., Ltd.
Last Modified on7 August 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note